Form 4: Syndax Pharmaceuticals CFO Acquires 1,250 Shares
SEC Form 4 Filing
Keith A. Goldan, CFO of Syndax Pharmaceuticals, recently purchased 1,250 shares of common stock at a price of $20.0298 per share.
Summary
- On June 14, 2024, Keith A. Goldan, the Chief Financial Officer of Syndax Pharmaceuticals Inc. (SNDX), acquired 1,250 shares of common stock.
- The purchase price was $20.0298 per share.
- Following the transaction, Goldan directly owns 52,623 shares of Syndax Pharmaceuticals.
Sentiment
Score: 5
Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is neutral as it is a standard regulatory filing.
Industry Context
This is a routine disclosure of an insider transaction. Insider buying can sometimes be seen as a positive signal, indicating management's confidence in the company's future prospects, but it is only one data point among many to consider when evaluating a stock.
Stakeholder Impact
- The purchase could be viewed positively by shareholders as it signals confidence from the CFO.
Key Dates
| Date | Description |
|---|---|
| 06/14/2024 | Date of the stock purchase transaction. |
| 06/17/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.